Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-513

https://www.bioworld.com/articles/434640-mesoblast-reports-83-survival-in-ventilator-dependent-covid-19-patients-following-stem-cell-therapy

That is a great find. The interview needs to be read very carefully (again) by many posters. The interview goes into more depth than the quotes used as part of the ASX announcements.

SI addresses all the concerns regarding the condition of the patients and the outcomes. Specifically, he mentioned that the other treatments afforded these patients was the same treatment that others, that sadly died, had received. So this treatment was most definitely ineffective. The survival of the patients was certainly down to the administration of Remestemcel-L.

The confidence was oozing out of every word and as we know, he is loathe to over-exuberance. The next few weeks will most certainly cause the doubters to have a serious rethink about their misgivings.

All IMHO.